RegulationCorporate GovernanceHealth company blames Sarbox for delisting

Health company blames Sarbox for delisting

Biopharmaceutical company says compliance to much of a burden

Sarbanes-Oxley
corporate governance rules have been blamed by
Vernalis, the speciality
biopharmaceutical company, as the reason for its decision to delisted from the
Nasdaq market.

The company, is also listed on the LSE, a listing it said would protect
investors.

Vernalis is set to file its application to delist from the tech-heavy index
by the end of next week and the delisting will come into effect ten days later.

It has decided to delist despite a ‘buy’ signal from broker Goldman Sachs.

Further reading:

Sarbox compliance seen as positive

Global audit fees rocket 345% over five years

US audit quality body defends Sarbox

Related Articles

Corporate governance: staying ahead in accountancy

Corporate Governance Corporate governance: staying ahead in accountancy

3m Alia Shoaib, Reporter
One in 20 audit firms quit as market evolves

Audit One in 20 audit firms quit as market evolves

1y Kevin Reed, Writer
Colin: #EURef bankers a problem

Business Regulation Colin: #EURef bankers a problem

1y Taking Stock
PwC and Deloitte chiefs sign Remain letter

Business Regulation PwC and Deloitte chiefs sign Remain letter

1y Kevin Reed, Writer
Leader: Audit competition drives change, not necessarily quality

Accounting Firms Leader: Audit competition drives change, not necessarily quality

2y Kevin Reed, Writer
EU audit reform to open up £10bn market for firms

Accounting Firms EU audit reform to open up £10bn market for firms

2y Richard Crump, Writer
Best Practice: Saffery Champness managing partner Rob Elliott

Accounting Firms Best Practice: Saffery Champness managing partner Rob Elliott

2y Calum Fuller, Reporter
Standard Life Investments opposes EY's appointment as Shell auditors at AGM

Accounting Firms Standard Life Investments opposes EY's appointment as Shell auditors at AGM

2y Richard Crump, Writer